Who founded Adaptyx Biosciences, Inc.?

Adaptyx Biosciences, Inc. was founded by Vijit Sabnis, Alex Yoshikawa, Pawan Kapur, H. Tom Soh, Joseph M. DeSimone in 2022.

Who are Adaptyx Biosciences, Inc.'s investors?

Adaptyx Biosciences, Inc.'s investors include AIN Ventures, Humba Ventures, Overwater Ventures Llc, Chemistry, Craft Ventures, Pace Capital.

Adaptyx Biosciences, Inc.

Founded 2022 · 19 employees on LinkedIn · 6 known investors

Find your way into Adaptyx Biosciences, Inc.

3,348 people in our graph share verified history with the Adaptyx Biosciences, Inc. team — schools, employers, funds. One of them is your warm intro.

Samir Kaulunlockedknows Pawan Kapur · together at Mojo Vision (overlapped)

×5knows the team · via Stanford Health Care

×2knows the team · via Kaiser Permanente

×4knows the team · via Khosla Ventures

Adaptyx develops a minimally-invasive wearable dermal patch that continuously measures biomarkers in interstitial fluid using an array of programmable molecular switches. The continuous data feeds algorithms intended to help clinicians make timelier decisions and reduce avoidable complications and hospital readmissions, replacing traditional lab draws and repeat clinic visits.

Biotech Digital Health Medical Devices

Founders & leadership

Adaptyx Biosciences, Inc. was founded in 2022 by Vijit Sabnis, Alex Yoshikawa, Pawan Kapur, H. Tom Soh, and Joseph M. DeSimone.

Vijit Sabnis Co-Founder & CEOInvestor at 1955 Capital

Alex Yoshikawa Co-Founder & Chief Science OfficerAlex Yoshikawa is Co-Founder and Chief Science Officer of Adaptyx Biosciences, bringing over a decade of research experience in biosensing and biomolecular engineering. He leads the development of the company's wearable dermal patch technology for continuous molecular monitoring.

Pawan Kapur Co-Founder & Chief Technology OfficerPawan Kapur is co-founder and CTO of Adaptyx, a digital health company developing wearable biomarker measurement devices. He has built multiple startups and leads R&D and product development; his background spans semiconductor devices, medical devices, wearables, and process technology, with approximately 90 patent filings and 65 publications.

H. Tom SohCo-Founder & Scientific Advisor

Joseph M. DeSimoneCo-Founder & Scientific Advisor

Daniel Grossman Chief Medical & Business OfficerDaniel Grossman is Chief Medical and Business Officer at Adaptyx. He has practiced medicine in both U.S. and international low-resource healthcare settings and has developed networks across multiple healthcare environments.

Investors · 6

AIN Ventureslisted by AIN VenturesNew York · $500K – $1M

How we know: AIN Ventures's portfolio page · Not right? Tell us

Humba Ventureslisted by Humba VenturesSan Francisco · $750K – $1.5M

How we know: Humba Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Overwater Ventures Llclisted by Overwater Ventures LlcPalo Alto · $400K – $2M

How we know: Overwater Ventures Llc's portfolio page · the VCSheet dataset · Not right? Tell us

ChemistryreportedSan Francisco

How we know: press coverage · Not right? Tell us

Craft VenturesreportedSan Francisco · $50K – $50M

How we know: press coverage · Not right? Tell us

Pace CapitalreportedNew York

How we know: press coverage · Not right? Tell us

Competitors · 3

by search overlap

Bioworld10 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

AltrixBio10 shared keywordsAltrixBio develops AJN003, a non-systemic, once-daily oral therapy for type 2 diabetes and related metabolic conditions that transiently coats the stomach and upper intestine to shift nutrient sensing and trigger a metabolic reset similar to bariatric surgery. The drug targets glycemic control and weight loss and is positioned as a complement or alternative to incretin-based (GLP-1) treatments, with potential applications in broader cardiometabolic diseases.

Fortis Life Sciences9 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.

Companies competing with Adaptyx Biosciences, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Adaptyx Biosciences, Inc. do?: Adaptyx develops a minimally-invasive wearable dermal patch that continuously measures biomarkers in interstitial fluid using an array of programmable molecular switches. The continuous data feeds algorithms intended to help clinicians make timelier decisions and reduce avoidable complications and hospital readmissions, replacing traditional lab draws and repeat clinic visits.
Who founded Adaptyx Biosciences, Inc.?: Adaptyx Biosciences, Inc. was founded by Vijit Sabnis, Alex Yoshikawa, Pawan Kapur, H. Tom Soh, Joseph M. DeSimone in 2022.
Who are Adaptyx Biosciences, Inc.'s investors?: Adaptyx Biosciences, Inc.'s investors include AIN Ventures, Humba Ventures, Overwater Ventures Llc, Chemistry, Craft Ventures, Pace Capital.